Goodsurance
ES

Drug prices & Part D

CMS Finalizes Mandatory Model to Tie Medicare Part B Drug Prices to International Benchmarks

A five-year payment test launching January 1, 2027, will require drug manufacturers to pay rebates when what they charge Medicare exceeds prices paid in 19 other countries, affecting about one quarter of Original Medicare enrollees.

By the Goodsurance editorial teamOctober 1, 2026

The Centers for Medicare and Medicaid Services finalized the Global Benchmark for Efficient Drug Pricing model, known as GLOBE, on September 30, 2026. The model is mandatory for manufacturers of eligible Part B drugs and will run from January 1, 2027, through March 31, 2032.

Under GLOBE, CMS will compare what Medicare pays for certain physician-administered drugs to net prices paid for the same medicines in 19 reference countries, including Canada, Germany, Japan, and the United Kingdom. When the international benchmark is lower, manufacturers must pay a rebate that reduces net Medicare spending on those drugs.

CMS just finalized a program tying certain Medicare Part B drug prices to what 19 other countries pay. It covers about 1 in 4 Original Medicare enrollees and starts January 2027.

The model applies to a randomly selected group of ZIP code tabulation areas representing about 25 percent of Original Medicare Part B enrollees. Eligible drugs are single-source medicines and sole-source biologicals from oncology, rheumatology, immunology, ophthalmology, and endocrinology, each with at least 100 million dollars in annual Original Medicare spending. Biosimilars, orphan-only drugs, plasma-derived products, and certain cell and gene therapies are excluded.

CMS projects the model will produce 440 million dollars in net Medicare Part B spending savings over the seven-year payment period. For beneficiaries in participating areas, the practical effect would be a reduction in their 20 percent Part B drug coinsurance, since that share is calculated as a percentage of a lower effective price. CMS expects those savings to begin reaching enrollees starting April 1, 2027.

The GLOBE model is the latest step CMS has taken to narrow the gap between what Medicare pays for certain drugs and what other high-income countries pay for the same treatments.

In plain words

The federal government just finalized a new Medicare program called GLOBE. Starting January 1, 2027, it applies to some Medicare Part B drugs. Those are medicines given in a doctor's office or clinic, not picked up at a pharmacy. The program compares what Medicare pays for a drug to what 19 other countries pay for the same drug. If Medicare pays more, the drug company must pay Medicare a rebate. About 1 in 4 people on Original Medicare live in areas covered by this program. The program is expected to save Medicare 440 million dollars over seven years. People in those areas could pay a little less out of pocket for certain drugs starting April 1, 2027.

Source: CMS
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Biotech Industry Group Files Second Lawsuit to Block Medicare's GLOBE Drug Pricing Model

BIO and two California biotech groups sued CMS on November 6, arguing the program exceeds legal authority. A first challenge from PhRMA filed in October remains pending.

November 12, 2026

Drug prices & Part D

KFF: Medicare's 340B Drug Payment Cut Reduces Revenue for Safety-Net Hospitals While Raising It for For-Profit Ones

Now that the 2027 outpatient rule is final, a KFF analysis finds the 340B reimbursement cut falls hardest on hospitals that serve low-income patients, while for-profit hospitals see a net gain.

November 11, 2026

Drug prices & Part D

Medicare Drug Price Negotiation Rules Are Now Permanent, Federal Register Shows

The CMS-4215-F final rule, published today, converts the negotiation program from administrative guidance into binding federal regulation for every drug-price cycle starting in 2029, and requires Part D plans to cover negotiated-price drugs on their formularies.

November 9, 2026

Drug prices & Part D

Third Medicare Drug Negotiation Cycle Closes, Including Part B Doctor-Office Drugs for the First Time

The formal negotiation period for 15 drugs ended November 1; CMS must publish any agreed-upon maximum fair prices by November 30, including the first-ever negotiated prices for drugs given in doctors' offices.

November 1, 2026

Drug prices & Part D

Average Medicare Part D Stand-Alone Premium Projected to Rise 50 Percent for 2027, KFF Finds

A KFF analysis published today finds the average monthly premium for stand-alone Part D drug plans is on track to climb from 34 dollars to 51 dollars for 2027, with deductibles also rising sharply, for enrollees who do not switch plans before December 7.

October 30, 2026

Drug prices & Part D

Study: Medicare Drug Price Negotiations Cut Costs for Most Enrollees, but Not for Those Already Hitting the Annual Spending Limit

A research letter in Annals of Internal Medicine finds that patients on six of the first ten negotiated Part D drugs saw out-of-pocket costs fall 26 to 49 percent, while patients on the three highest-priced negotiated drugs saw no additional benefit because they were already reaching the annual cap.

October 24, 2026